We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Collaboration Aims to Increase Yield of Anti-Zika Antibody
Product News

New Collaboration Aims to Increase Yield of Anti-Zika Antibody

New Collaboration Aims to Increase Yield of Anti-Zika Antibody
Product News

New Collaboration Aims to Increase Yield of Anti-Zika Antibody


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "New Collaboration Aims to Increase Yield of Anti-Zika Antibody"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Batavia Biosciences has announced an agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines. Initially, Batavia will deploy the system for production of a potent Zika virus-neutralizing antibody, working in collaboration with Vanderbilt University Medical Center (VUMC) and IDBiologics, a company which focuses on developing human antibodies to infectious diseases. “We’re excited to work with Batavia to move this promising Zika antibody therapy one step closer to the clinic,” stated James Crowe Jr, M.D., Director of the Vanderbilt Vaccine Center.

The Zika virus-neutralizing antibody was discovered three years ago by VUMC researchers in collaboration with colleagues at Washington University School of Medicine. The group reported the isolation of a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus. The VUMC antibody, dubbed ZIKV-117, binds to an epitope or “part of” the Zika virus in a way that no other antibody has to date. “Developing high yield antibody producer CHO lines is difficult and expensive,” added Robert Carnahan, Ph.D., Director of Vanderbilt Antibody and Protein Resource. “That is why this new solution is so important to the anti-Zika antibody project.”


Advertisement